AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
CD19 directed chimeric antigen receptor T cell (CART19) therapy has shown remarkable response rates in relapsed/refractory large B cell lymphoma (LBCL), but limited CART persistence restricts durable responses, while cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) constrain its therapeutic index. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) regulate T cell receptor and inflammatory signaling, but their effects on CART fitness and inflammation are undefined. We aim to 1) assess the association between baseline plasma EPA+DHA and clinical outcomes after axicabtagene ciloleucel (axi-cel) and 2) define the direct functional effects and molecular mechanisms of EPA+DHA in CART19 cells.
We retrospectively analyzed 30 patients with LBCL treated with axi-cel. Plasma was collected before lymphodepletion. Patients were classified by median baseline EPA+DHA fraction as high (≥1.94%; n=16) or low (≤1.93%; n=14), and outcomes were assessed in exploratory unadjusted analyses. Overall response rates were similar (87.5% vs 85.7%), whereas the EPA+DHA-high group had longer unadjusted progression-free survival (median not reached vs 6.7 months, log-rank p=0.0067) and overall survival (median not reached vs 43 months, log-rank p=0.0276). Among patients who developed ICANS, higher baseline plasma EPA+DHA levels were associated with shorter ICANS duration (Spearman r=-0.41, p=0.048; n=24).
To define direct effects of EPA/DHA on CART cells, healthy donor T cells were primed with EPA+DHA (100 µM each) during CD3/CD28 activation. EPA/DHA was then removed before lentiviral transduction, and CART19-28ζ cells (similar to axi-cel) were generated. Against CD19+ OCI-Ly7, LBCL cell lines, EPA/DHA-primed CART19 showed enhanced cytotoxicity across multiple effector-to-target (ET) ratios (p<0.05). In a 4-hour intracellular cytokine assay, EPA/DHA-primed CART19 showed higher proportions of T cells expressing IL2, perforin, and TNFα (p=0.006, p=0.02, p=0.04, respectively). EPA/DHA-priming also increased antigen-specific proliferation on days 3 and 5 (p=0.03, p=0.002, respectively), with lower proportions of PD1 and LAG3 (both p<0.05) and showed a shift toward lower inhibitory receptor co-expression, with more cells expressing 0-1 and fewer expressing PD1, CTLA4, LAG3 and TIM3. Bulk RNA-seq showed reduced mitotic cell cycle, RHO GTPase, cytoskeletal, and chromatin regulatory programs.13C glucose tracing showed that EPA/DHA increased citrate M+4 and aspartate M+2 without changing citrate M+2, lactate, or palmitate, consistent with increased mitochondrial respiration.
We next tested the durability under repeated antigen stimulation. OCI-ly7 cells were added to CART19 at a 1:1 ET ratio on days 0, 2, 4, and 6, CART19 were isolated on day 7. Although cytotoxicity was comparable between groups, EPA/DHA-primed CART19 showed higher proportions of cells expressing IL2 and TNFα (p=0.01, p=0.002, respectively). Bulk RNA-seq showed reduced expression of exhaustion associated genes including PDCD1, LAG3, CTLA4, NR4A1, and NR4A3, with increased KLF2.
Lastly, to test whether an over-the-counter EPA/DHA supplement could enhance CART19 function, we collected PBMCs from a healthy donor before and after two weeks of oral omega-3 supplementation (2,560 mg/day) under an IRB-approved protocol. CART19 generated after supplementation showed better expansion on day 5 following OCI-Ly7 stimulation (p=0.0398). They also showed an increased CD4+CD45RA+CCR7+ population (p=0.0166) and reduced CD4+ TEMRA cells (p=0.0247), consistent with a less-differentiated phenotype.
In summary, higher baseline EPA/DHA was associated with longer PFS and OS and shorter ICANS duration after axi-cel. Mechanistically, EPA+DHA favored a less basally activated CART19 state with better functional durability following repeated antigen exposure, and EPA+DHA enhanced mitochondrial respiration. In a healthy donor, CART19 cells generated after two weeks of oral EPA/DHA supplementation showed functional improvements consistent with those observed following EPA/DHA priming. Because EPA and DHA are widely available and require no modification of the CAR construct, viral vector, or manufacturing platform, we are planning a prospective trial of oral EPA+DHA supplementation before leukapheresis in patients with LBCL receiving CART19 therapy.